AHA Coding Clinic® for HCPCS - 2018 Issue 2; For Your Information
Changes to biosimiliar biological product HCPCS codes
On April 1, 2018, HCPCS code Q5102 was replaced with HCPCS codes Q5103 and Q5104. For a listing of the HCPCS code changes and their code descriptors, see the table below. HCPCS Code Long Descriptor Termination Date Q5102 Injection, infliximab, biosimilar, 10 mg 03/31/2018 Q5103 Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg Q5104 Injection, infliximab-abda, biosimilar, (renflexis), 10 mg ...
Subscribe or sign in to view the full article.
Article Overview
This short article covers a HCPCS coding update for biosimilar biological products effective in 2018. It is intended for coders, billers, and reimbursement staff who need to track code maintenance changes and identify which HCPCS identifiers are affected.
Why This Topic Matters
Keeping up with HCPCS code changes is important for accurate claims processing, charge capture, and reference maintenance. Articles like this help users monitor code replacements and other coding updates without having to search through multiple source documents.
What You Will Learn
- What the article is about at a general level
- Which HCPCS code update is discussed
- When the update took effect
- How the article presents the affected codes in a summary table
Who Should Read This
- Medical coders
- Billing staff
- Reimbursement specialists
- Practice managers
- Healthcare compliance staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com